Vascular Biogenics Ltd (NASDAQ:VBLT) was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 127,000 shares, an increase of 10.2% from the May 15th total of 115,200 shares. Approximately 0.6% of the shares of the stock are short sold. Based on an average daily volume of 91,300 shares, the short-interest ratio is presently 1.4 days.
Several analysts have recently weighed in on VBLT shares. Oppenheimer dropped their price objective on shares of FedEx from $192.00 to $176.00 and set an “outperform” rating for the company in a report on Thursday, June 27th. HC Wainwright dropped their price objective on shares of ImmunoGen from $7.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, May 16th. Chardan Capital reissued a “hold” rating and issued a $3.00 price target on shares of Vascular Biogenics in a report on Thursday, May 16th. CIBC assumed coverage on shares of Vascular Biogenics in a report on Thursday, June 27th. They issued an “outperform” rating for the company. Finally, ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. Vascular Biogenics currently has an average rating of “Hold” and an average target price of $2.38.
Several institutional investors have recently added to or reduced their stakes in the company. RBF Capital LLC acquired a new position in shares of Vascular Biogenics during the 4th quarter worth about $353,000. First Republic Investment Management Inc. increased its stake in shares of Vascular Biogenics by 7.4% during the 1st quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 10,000 shares during the last quarter. Menta Capital LLC acquired a new position in shares of Vascular Biogenics during the 1st quarter worth about $35,000. Finally, Athena Capital Advisors LLC acquired a new position in shares of Vascular Biogenics during the 1st quarter worth about $25,000. Institutional investors own 6.85% of the company’s stock.
Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Vascular Biogenics had a negative net margin of 2,724.02% and a negative return on equity of 31.69%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $2.30 million. Equities research analysts anticipate that Vascular Biogenics will post -0.53 earnings per share for the current year.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
See Also: The risks of owning bonds
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.